Diagnostics company Meridian Bioscience (NASDAQ:VIVO) has received U.S. Food and Drug Administration clearance for a test to detect bacteria commonly associated with Legionnaires’ disease.
Legionnaires’ disease is a severe lung inflammation caused by an infection.
Cincinnati, Ohio-area Meridian said the test, called TRU Legionella, is an important addition to its respiratory product portfolio.
“This new assay solidifies our position as a leader in rapid, accurate testing methods for infectious disease testing,” CEO Jack Kraeutler said.
Meridian said the bacteria associated with Legionnaires’ disease is implicated in 5 percent to 8 percent of the 4 million to 5 million cases of community-acquired pneumonia per year in the U.S.
In December, Meridian received FDA clearances for tests for C. difficile and group B streptococcus.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
[Photo by flickr user Spec-ta-cles]